Skip to content
DraconiticResearch
Search Sources API
197,688 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BY-NC-NDBMC nephrology

Rituximab and corticosteroids for M-protein-negative PGNMID: case report.

  • Zhuolin Huang1
  • Shuopeng Yang1
  • Jun Cai2,3
  • Fengying Tang4,5
5 affiliations
  1. 1Guangdong Medical University, Zhanjiang, Guangdong, People's Republic of China.
  2. 2Jinan University, No. 601, Huangpu Avenue West Tianhe District, Guangzhou, Guangdong Province, 510632, People's Republic of China. [email protected].
  3. 3Huizhou Central People's Hospital, No. 41, Eling Road, Huicheng District, Huizhou, Guangdong Province, 516001, People's Republic of China. [email protected].
  4. 4Guangdong Medical University, Zhanjiang, Guangdong, People's Republic of China. [email protected].
  5. 5Huizhou Central People's Hospital, No. 41, Eling Road, Huicheng District, Huizhou, Guangdong Province, 516001, People's Republic of China. [email protected].
Read full textPDFDOICite

Abstract

Background

We report a case of a 69-year-old patient negative for serum M-protein who was diagnosed with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) via renal biopsy.Case presentation

A 69-year-old male presented with hematuria, edema, and rapidly progressive renal failure. Serum M-protein was negative, but renal biopsy confirmed IgG3-κ PGNMID with intense C3 deposition and an MPGN-like pattern. Rituximab was initiated, but due to a pulmonary infection, only one of the planned rituximab doses was administered. After infection resolution, the patient's renal function gradually improved (serum creatinine from 914 to 134 µmol/L) under long-term corticosteroid maintenance. Whether this improvement resulted from the single rituximab dose, prolonged corticosteroids, resolution of sepsis-associated AKI, or natural disease course remains uncertain. This case underscores that PGNMID, though rare, should be considered in seronegative patients with unexplained glomerulonephritis, and highlights the critical role of renal biopsy.Conclusions

PGNMID should be considered in rapidly progressive glomerulonephritis, even when M-protein is negative. In this patient, a single reduced dose of rituximab combined with prolonged corticosteroids was associated with a favorable renal outcome, suggesting that a B-cell-directed, clone-directed approach may be a reasonable option worth further evaluation in seronegative PGNMID. Nonetheless, causality cannot be established from a single case, and the relative contributions of the individual therapies remain uncertain. Further studies are needed to define the optimal treatment for this rare entity.

Related

  1. Case Report: Cytomegalovirus retinitis in an HIV-negative patient with splenic mantle cell lymphoma treated with bendamustine-rituximab
    Yi-Hsien Tsai, Hsien-Chung Lin, Wen-Chi Yang +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textEpidemiology & public healthCrossref
  2. Nonadherence to inhaled corticosteroids is associated with negative mepolizumab response.
    Mohammed Ghazi Almutairi, John Marriott, Zahraa Jalal +8
    ERJ open researchPeer-reviewedCC BYFull text1 citedPhysiologyEurope PMC
  3. Case Report: Effective use of rituximab in children with steroid-resistant/dependent idiopathic pulmonary hemosiderosis: description of two cases and literature review
    Sha Li, Tinghua Liu, Rongqiong Ou +3
    Frontiers in pediatricsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Rituximab-induced Acute Thrombocytopenia in Systemic Sclerosis: A Case Report of Two Cases
    Chihiro Saiki, Masahiro Ayano, Yuki Kojima +3
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedGeneral medicineJ-STAGE
  5. Pneumocystis Jirovecii Pneumonia Associated with Prolonged CD4-positive T-cell Depletion after Bendamustine-Rituximab Therapy: A Case Report
    Haruka Zukeyama, Shuhei Ideguchi, Tomo Kiyuna +7
    Internal MedicinePeer-reviewedCC BY-NC-NDFull text1 citedEpidemiology & public healthJ-STAGE

Cite

BibTeXRIS
BibTeX
@article{huang2026rituximab,
  title = {{Rituximab and corticosteroids for M-protein-negative PGNMID: case report.}},
  author = {Zhuolin Huang and Shuopeng Yang and Jun Cai and Fengying Tang},
  journal = {BMC nephrology},
  year = {2026},
  month = jul,
  doi = {10.1186/s12882-026-05225-0},
  url = {https://europepmc.org/article/MED/42907772},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Rituximab and corticosteroids for M-protein-negative PGNMID: case report.
AU  - Zhuolin Huang
AU  - Shuopeng Yang
AU  - Jun Cai
AU  - Fengying Tang
PY  - 2026
DA  - 2026/07/01
JO  - BMC nephrology
DO  - 10.1186/s12882-026-05225-0
UR  - https://europepmc.org/article/MED/42907772
AB  - Background  We report a case of a 69-year-old patient negative for serum M-protein who was diagnosed with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) via renal biopsy.Case presentation  A 69-year-old male presented with hematuria, edema, and rapidly progressive renal failure. Serum M-protein was negative, but renal biopsy confirmed IgG3-κ PGNMID with intense C3 deposition and an MPGN-like pattern. Rituximab was initiated, but due to a pulmonary infection, only one of the planned rituximab doses was administered. After infection resolution, the patient's renal function gradually improved (serum creatinine from 914 to 134 µmol/L) under long-term corticosteroid maintenance. Whether this improvement resulted from the single rituximab dose, prolonged corticosteroids, resolution of sepsis-associated AKI, or natural disease course remains uncertain. This case underscores that PGNMID, though rare, should be considered in seronegative patients with unexplained glomerulonephritis, and highlights the critical role of renal biopsy.Conclusions  PGNMID should be considered in rapidly progressive glomerulonephritis, even when M-protein is negative. In this patient, a single reduced dose of rituximab combined with prolonged corticosteroids was associated with a favorable renal outcome, suggesting that a B-cell-directed, clone-directed approach may be a reasonable option worth further evaluation in seronegative PGNMID. Nonetheless, causality cannot be established from a single case, and the relative contributions of the individual therapies remain uncertain. Further studies are needed to define the optimal treatment for this rare entity.
SN  - 1471-2369
ER  -